Cargando…

Antitumor Activity of Combination Therapy with Metformin and Trametinib in Non-Small Cell Lung Cancer Cells

Metformin has been widely used as an antidiabetic drug, and reported to inhibit cell proliferation in many cancers including non-small cell lung cancer (NSCLC). In NSCLC cells, metformin suppresses PI3K/AKT/mTOR signaling pathway, but effect of metformin on RAS/ RAF/MEK/ERK signaling pathway is cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ko, Eunjeong, Baek, Seungjae, Kim, Jiwon, Park, Deokbae, Lee, Youngki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Developmental Biology 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375979/ https://www.ncbi.nlm.nih.gov/pubmed/32734128 http://dx.doi.org/10.12717/DR.2020.24.2.113

Ejemplares similares

Antitumor Effect of Metformin in Combination with Binimetinib on Melanoma Cells
por: Lee, Eunsung, et al.
Publicado: (2021)

Synergistic Enhancement of Paclitaxel-induced Inhibition of Cell Growth by Metformin in Melanoma Cells
por: Ko, Gihyun, et al.
Publicado: (2019)

Metformin Synergistically Potentiates the Antitumor Effects of Imatinib in Colorectal Cancer Cells
por: Lee, Jaeryun, et al.
Publicado: (2017)

Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells
por: Kim, Taewan, et al.
Publicado: (2018)

Biphasic Activity of Chloroquine in Human Colorectal Cancer Cells
por: Park, Deokbae, et al.
Publicado: (2014)

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
por: Weart, Thomas C, et al.
Publicado: (2018)

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Metformin Induces Lipogenesis and Apoptosis in H4IIE Hepatocellular Carcinoma Cells
por: Park, Deokbae, et al.
Publicado: (2023)

Metformin Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Non-Small Cell Lung Cancer Cells
por: Cao, Nini, et al.
Publicado: (2020)

Severe Epistaxis Secondary to Dabrafenib and Trametinib Toxicity in Non-small Cell Lung Carcinoma With Small Bowel Metastasis
por: Gullapalli, Keerthi, et al.
Publicado: (2021)

Blockage of Autophagy Rescues the Dual PI3K/mTOR Inhibitor BEZ235-induced Growth Inhibition of Colorectal Cancer Cells
por: Oh, Iljoong, et al.
Publicado: (2016)

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
por: Vujic, Igor, et al.
Publicado: (2014)

Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation
por: Dotsu, Yosuke, et al.
Publicado: (2020)

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience
por: Khunger, Arjun, et al.
Publicado: (2018)

Advances in metformin-based metabolic therapy for non-small cell lung cancer
por: Chen, Na, et al.
Publicado: (2022)

Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report
por: Pan, Janet
Publicado: (2019)

Novel Dimer Derivatives of PF-543 as Potential Antitumor Agents for the Treatment of Non-Small Cell Lung Cancer
por: Kim, Su Bin, et al.
Publicado: (2022)

Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models
por: Shi, Shujing, et al.
Publicado: (2013)

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib
por: Noeparast, Amir, et al.
Publicado: (2016)

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
por: Adachi, Yuta, et al.
Publicado: (2020)

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations
por: Odogwu, Lauretta, et al.
Publicado: (2018)

Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer
por: Guo, Liangran, et al.
Publicado: (2012)

Rapamycin and trametinib: a rational combination for treatment of NSCLC
por: Sun, Chao-Yue, et al.
Publicado: (2021)

Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro
por: Jin, Xi-Feng, et al.
Publicado: (2021)

Primary Melanoma of the Lung Treated with Surgery, Dabrafenib and Trametinib
por: Landgraf, Layla G., et al.
Publicado: (2020)

Prognostic value of metformin for non-small cell lung cancer patients with diabetes
por: Xu, Tongbai, et al.
Publicado: (2018)

Progress in the application and mechanism of metformin in treating non-small cell lung cancer
por: Li, Chan, et al.
Publicado: (2017)

Addition of metformin to non‐small‐cell lung cancer patients with or without diabetes
por: Chen, Hua‐Fen, et al.
Publicado: (2022)

Antitumor Therapy under Hypoxic Microenvironment by the Combination of 2-Methoxyestradiol and Sodium Dichloroacetate on Human Non-Small-Cell Lung Cancer
por: Romero, Yair, et al.
Publicado: (2020)

Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells
por: Pei, Jun, et al.
Publicado: (2017)

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells
por: Osrodek, Marta, et al.
Publicado: (2020)

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
por: Luke, Jason J, et al.
Publicado: (2014)

Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report
por: Sundaram, Vinita Ruth, et al.
Publicado: (2018)

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
por: Minor, David R., et al.
Publicado: (2015)

Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E‐positive non–small cell lung cancer: A case report
por: Taniguchi, Yoshihiko, et al.
Publicado: (2023)

Antitumor Effect of Embryonic Stem Cells in a Non-Small Cell Lung Cancer Model: Antitumor Factors and Immune Responses
por: Dong, Wei, et al.
Publicado: (2013)

Successful re-challenge of dabrafenib-trametinib combination therapy in advanced BRAF(V600E)-mutant non-small cell lung cancer after previous cytotoxic chemotherapy, targeted therapy, and immunotherapy: a case report
por: Xue, Yaran, et al.
Publicado: (2022)

Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023)

Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report
por: Li, Dan, et al.
Publicado: (2022)

Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer
por: Wang, Haocheng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bt76bjd1jrit70ur27o04jat17